• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Pessoal
    • Webmail
    • Área de Docentes
    • Área de Não-Docentes
  • Estudantes
    • Webmail
    • Moodle
    • NetP@
    • Biblioteca
    • Escola Doutoral
    • Serviços Académicos
    • Trabalhar no IHMT

IHMT

Instituto de Higiene e Medicina Tropical

  • O Instituto
    • Missão
    • História
    • Mensagem do Diretor
    • Órgãos de governo
    • Docentes e investigadores
    • Unidades de Ensino e de Investigação
  • Ensino
    • Doutoramentos
    • Mestrados
    • Cursos de Especialização
    • Formação transversal
    • Cursos de Curta Duração
    • Ensino à Distância
    • Apoio ao Desenvolvimento
    • Serviços académicos
  • Investigação
    • Centro GHTM
    • Unidade de Clínica Tropical
    • Unidade de Microbiologia Médica
    • Unidade de Parasitologia Médica
    • Unidade de Saúde Pública Global
    • Serviço de Interesse Comum
    • Biobanco
    • Centro Colaborador da OMS
    • Publicações
  • Serviços e gestão
    • Biblioteca
    • Sistema de Qualidade
    • Estatutos e regulamentos
    • Relatórios
    • Contratos públicos
    • Recursos humanos
      • Concursos e bolsas
      • Contratos
      • Avaliação e Desempenho
        • Processo Eleitoral da Comissão Paritária
      • Mobilidade
  • Doenças Tropicais
    • Consulta do Viajante
    • Glossário
    • Museu
    • Vídeos
    • MosquitoWeb
  • Comunidade
    • Cooperação e Desenvolvimento
    • Formação
    • Parcerias
  • Contactos
  • Português
  • English
Home / Archives for Van Laethem K

Van Laethem K

High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba.

  • Autores: Aleman Y, Álvarez D, Aragonés C, Campos J, Correa C, Fonseca C, Kourí V, Limia C, Perez J, Perez L, Schrooten Y, Soto Y, Van Laethem K, Vandamme AM, Vinken L
  • Ano de Publicação: 2012
  • Journal: Journal of Clinical Virology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25397499

INTRODUCTION:
Emergence of HIV-1 drug resistance may limit the sustained benefits of antiretroviral therapy (ART) in settings with limited laboratory monitoring and drug options. The objective is to implement the surveillance of drug resistance and subtypes in HIV-1 patients failing ART in Cuba.
Ler mais

Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time

  • Autores: Assel M, Boucher CA, De Luca A, Fabbiani M, Frentz D, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Van de Vijver DA, Van Laethem K, Vandamme AM, Zazzi M
  • Ano de Publicação: 2010
  • Journal: PLoS One
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparison+of+HIV-1+Genotypic+Resistance+Test+Interpretation+Systems+in+Predicting+Virological+Outcomes+Over+Time

BACKGROUND: Several decision support systems have been developed to interpret HIV-1 drug resistance genotyping results. This study compares the ability of the most commonly used systems (ANRS, Rega, and Stanford’s HIVdb) to predict virological outcome at 12, 24, and 48 weeks. METHODOLOGY/PRINCIPAL FINDINGS: Included were 3763 treatment-change episodes (TCEs) for which a HIV-1 genotype was […]
Ler mais

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

  • Autores: Camacho RJ, Covens K, Palma AC, Snoeck J, Van Laethem K, Vandamme AM
  • Ano de Publicação: 2012
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=HIV-1+protease+mutation+82M+contributes+to+phenotypic+resistance+to+protease+inhibitors+in+subtype+G

OBJECTIVES:
The purpose of this study was the qualitative and quantitative assessment of the in vitro effect of HIV-1 protease (PR) mutation 82M on replication capacity and susceptibility to the eight clinically available PR inhibitors (PIs).
Ler mais

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

  • Autores: Asboe D, Bansi L, Camacho R, Codoñer FM, De Luca A, Di Giambenedetto S, Dunn D, Fanti I, Ghisetti V, Kaiser R, Prosperi MCF, Sönnerborg A, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
  • Ano de Publicação: 2013
  • Journal: Journal of Infectious Diseases
  • Link: http://jid.oxfordjournals.org/content/early/2013/01/11/infdis.jit017.abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20,323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Ler mais

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure

  • Autores: Beheydt G, Bruzzone B, Camacho RJ, De Luca A, Deforche K, Grossman Z, Imbrechts S, Incardona F, Libin P, Pironti A, Rhee SY, Ruiz L, Sangeda RZ, Shafer RW, Sönnerborg A, Theys K, Torti C, Van de Vijver DA, Van Laethem K, Van Wijngaerden E, Vandamme AM, Vercauteren J, Zazzi M
  • Ano de Publicação: 2013
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23523594

We previously modeled the in vivo evolution of human immunodeficiency virus-1 (HIV-1) under drug selective pressure from cross-sectional viral sequences. These fitness landscapes (FLs) were made by using first a Bayesian network (BN) to map epistatic substitutions, followed by scaling the fitness landscape based on an HIV evolution simulator trying to evolve the sequences from treatment naïve patients into sequences from patients failing treatment.
Ler mais

Study of the regimen-specific HIV-1 genotypic susceptibility score after treatment failure

  • Autores: Beheydt G, Camacho R, Carvalho AP, Diogo I, Grossman Z, Ram D, Rudich H, Van Laethem K, Vandamme AM, Zazzi M
  • Ano de Publicação: 2010
  • Journal: Antiviral Therapy
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=3&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Ler mais

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

  • Autores: Altmann A, Boucher CA, Brun-Vezinet F, Harrigan PR, Incardona F, Kaiser R, Lengauer T, Morris L, Obermeier M, Peres Y, Perno CF, Petroczi A, Phanuphak P, Pillay D, Prosperi M, Rosen-Zvi M, Schülter E, Shafer RW, Sönnerborg A, Struck D, Van Laethem K, Vandamme AM, Wensing AM, Zazzi M
  • Ano de Publicação: 2011
  • Journal: HIV medicine
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+response+to+antiretroviral+therapy+by+human+experts+and+by+the+EuResist+data-driven+expert+system+(the+EVE+study).

OBJECTIVES:
The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen plus optional patient information. The objective of this study was to compare the EuResist system vs. human experts (EVE) for the ability to predict response to treatment.
Ler mais

Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine

  • Autores: Beheydt G, Camacho R, Carvalho AP, Grossman Z, Levy I, Ram D, Rudich H, Van Laethem K, Vandamme AM, Vercauteren J
  • Ano de Publicação: 2010
  • Journal: Antiviral Therapy
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Ler mais

Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba

  • Autores: Abrahantes Y, Aleman Y, Alvarez A, Álvarez D, Aragonés C, Beheydt G, Campos J, Correa C, Dekeersmaeker N, Fonseca C, Imbrechts S, Kourí V, Martínez O, Perez J, Perez L, Schrooten Y, Soto Y, Van Laethem K, Vandamme AM, Vinken L
  • Ano de Publicação: 2013
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23416260

In Cuba, antiretroviral therapy rollout started in 2001 and antiretroviral therapy coverage has reached almost 40% since then. The objectives of this study were therefore to analyze subtype distribution, and level and patterns of drug resistance in therapy-naive HIV-1 patients.
Ler mais

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir

  • Autores: Aleixo MJ, Camacho RJ, Cavaco-Silva J, Cunha C, Faria D, Gomes P, Goncalves MF, Valadas E, Van Laethem K, Vandamme AM
  • Ano de Publicação: 2013
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/22977160

To investigate mutations selected in viruses from HIV-2-infected patients failing a highly active antiretroviral treatment (HAART) regimen including atazanavir/ritonavir.
Ler mais

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Footer

INSTITUTO DE HIGIENE E
MEDICINA TROPICAL
UNIVERSIDADE NOVA DE LISBOA
Rua da Junqueira, 100 1349-008 Lisboa
T +351 213 652 600
geral@ihmt.unl.pt

Consulta do Viajante e Medicina Tropical
T +351 213 652 630
T +351 213 652 690
T +351 91 182 37 48
T +351 91 182 44 67
medicina.viagens@ihmt.unl.pt

Ensino
Investigação
Medicina Tropical
Cooperação

Siga-nos

  • Facebook
  • LinkedIn
  • YouTube

Receber a “newsletter”

© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013